Business
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
RenovoGem™ Patients had Greater than 65% Reduction in Side Effects, which can Include Nausea, Fatigue, and Reduced White Blood Cells During Pancreatic Cancer
About this update from Renovorx, Inc.
[{"type":"text","content":"\nRenovoGem™ Patients had Greater than 65% Reduction in Side Effects, which can Include Nausea, Fatigue, and Reduced White Blood Cells During Pancreatic Cancer Treatment\n\nThese Data and Additional Secondary Endpoint Analyses to be Presented at American Association for Cancer Research (AACR) Annual Meeting on April 17, 2023\n\n LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that it will present detailed, open label, planned Phase III interim data analysis of its innovative RenovoGem therapy for pancreatic cancer patients at the American Association for Cancer Research (AACR) Annual Meeting on April 17, 2023 in Orlando, Florida.\n\nThe interim analysis shows a 6-month median overall survival benefit for patients. That is nearly a 60% improvement versus the study control arm and current standard of care: intravenous (IV) administration of gemcitabine and nab-paclitaxel for locally advanced pancreatic cancer (“LAPC”). RenovoGem patients also had greater than 65% reduction in adverse events. These can include nausea, fatigue, and a decline in white blood cells.\n\nTIGeR-PaC study Principal Investigator, Michael J. Pishvaian, M.D., Ph.D. at Johns Hopkins Medicine, said, “Results from the interim analysis echo the Phase I/II data and observational studies. The TIGeR-PaC clinical trial is ongoing, but it appears RenovoGem enhances patient survival and has fewer side effects than the standard of care treatment that impacts the entire body of a patient rather than the targeted treatment area. This is important because treatment of LAPC is often limited to systemic, high dose, IV chemotherapy. It often has debilitating side effects.”\n\nDr. Pishvaian added, “These positive results offer hope for a compelling new treatment option that could greatly benefit this important patient population and perhaps many others as the research advances.”\n\nRamtin Agah, MD, Chief Medical Officer and Founder of RenovoRx, said, “This planned, early interim data analysis is a critical look into our Phase III randomized study. When you compare the results with other approved and widely adopted drugs used for treatment of pancreatic cancer, our six-month median survival benefit is dramatically better than other options...